← Back to Search

Other

LabClasp Wearable Device for Monitoring in Healthy Individuals

N/A
Waitlist Available
Led By Virend Somers
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 day
Awards & highlights

Study Summary

This trial tests whether the LabClasp, a wearable device, can accurately measure blood lactate levels.

Who is the study for?
This trial is for healthy adults over 18 who can do high-intensity exercise, are not smokers, haven't been hospitalized recently, aren't in the ICU but have sepsis risk factors. They must be able to consent and agree to regular blood tests for lactate levels.Check my eligibility
What is being tested?
The study is testing LabClasp's technology to estimate blood lactate levels non-invasively during high-intensity exercise compared with traditional blood sampling methods.See study design
What are the potential side effects?
Since this trial involves non-invasive monitoring with LabClasp and regular blood draws, potential side effects may include discomfort at the sensor site and bruising or pain from blood sampling.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 day
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 day for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Blood [lactate] during incremental exercise
Blood [lactate] measurements in ICU patients

Trial Design

2Treatment groups
Experimental Treatment
Group I: Whole-body exercise in healthy adults (Aim 1)Experimental Treatment1 Intervention
Subjects will have blood [lactate] measurement obtained with the LabClasp device while completing an exercise stress test on a treadmill or bicycle.
Group II: ICU patients susceptible to developing sepsis (Aim 2)Experimental Treatment1 Intervention
Subjects will have blood [lactate] measurement obtained with the LabClasp device as frequently as required for clinical purposes

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,176 Previous Clinical Trials
3,758,001 Total Patients Enrolled
Virend SomersPrincipal InvestigatorMayo Clinic

Media Library

LabClasp (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05036122 — N/A
Healthy Subjects Research Study Groups: Whole-body exercise in healthy adults (Aim 1), ICU patients susceptible to developing sepsis (Aim 2)
Healthy Subjects Clinical Trial 2023: LabClasp Highlights & Side Effects. Trial Name: NCT05036122 — N/A
LabClasp (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05036122 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment currently in the process of enrolling participants?

"The data hosted on clinicaltrials.gov confirms that this particular medical trial is not currently accepting patients, having been posted on February 1st 2023 and last updated October 14th 2022. Nevertheless, there are 839 other trials actively recruiting participants as of now."

Answered by AI
~33 spots leftby Sep 2024